Skip to main navigation Skip to search Skip to main content

Microbiome-host communication via vaccenic acid modulates LRH-1/NR5A2 activity and ameliorates metabolic liver disease

  • Anna Pia Plazzo
  • , Verena Filz
  • , Michaela Prothiwa
  • , Rebekka Lambrecht
  • , M. Eugenia Delgado
  • , Jennifer R. Fleming
  • , Jerome Duschek
  • , Elia Pilgram
  • , Juliane Friedrich
  • , Raphael Eisenring
  • , Lea Kurtz
  • , Kerstin Stemmer
  • , Lotta K. Stenman
  • , Fabian Amaya Garcia
  • , Miriam Unterlass
  • , Olga Mayans
  • , Thomas Böttcher
  • , Thomas Brunner (Corresponding author)

Publications: Contribution to journal › Article › Peer Reviewed

Abstract

Interactions between microbiota and the host can profoundly affect human health. In particular, microbiota-derived metabolites influence liver physiology and contribute to the development of metabolic diseases, yet the molecular mechanisms underlying microbiome-host communication remain incompletely understood. Here, we identify bacterial lipids as modulators of the nuclear receptor Liver Receptor Homolog-1 (LRH-1/NR5A2), a regulator of hepatic metabolism. Lipid extracts from multiple bacterial species, including the probiotic Bifidobacterium animalis subsp. lactis B420TM, activated LRH-1, leading to the identification of the long-chain fatty acid vaccenic acid (VA) as a previously unrecognized endogenous LRH-1 ligand. VA directly bound the LRH-1 ligand-binding domain and stimulated receptor-dependent transcriptional activity. In high-fat diet-induced obese and hyperglycemic mice, VA-mediated LRH-1 activation improved glucose homeostasis and attenuated metabolic liver disease. Transcriptomic analyses revealed suppression of hepatic de novo lipogenesis as a principle downstream response to LRH-1 activation. Together, these findings establish a microbiota-LRH-1 signaling axis that links bacterial lipid metabolism to host metabolic regulation, identify VA as a functional LRH-1 agonist, and provide a mechanistic rationale for targeting LRH-1 in metabolic liver disease.

Original languageEnglish
JournalEMBO Molecular Medicine
DOIs
Publication statusE-pub ahead of print - 2026

Funding

The authors thank the entire Brunner group and the animal care takers of the Central Animal Facility for continuous support. This work was supported in part by a grant from the German Science Foundation (DFG, BR 3369/4-2). APP was supported by the Brigitte Schlieben Lange-Program, Baden Württemberg.

FundersFunder number
Deutsche Forschungsgemeinsachft (DFG)BR 3369/4-2

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Austrian Fields of Science 2012

    • 301306 Medical molecular biology
    • 104004 Chemical biology

    Cite this